Neoplasms

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Infections

Rare Diseases

Carcinoma

Liver Cirrhosis

Carcinoma, Hepatocellular

Hepatitis A

Hepatitis

Hepatitis B

Virus Diseases

Liver Diseases

Gastrointestinal Diseases

Hepatitis, Viral, Human

Communicable Diseases

Enterovirus Infections

Picornaviridae Infections

RNA Virus Infections

Blood-Borne Infections

Hepadnaviridae Infections

DNA Virus Infections

Fibrosis

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Herpes Simiae (B Virus)

All Drugs and Chemicals

Antibodies

Immunoglobulins

HBV infection status determined by enzyme-linked immuno-assay (ELISA)

HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).

Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).

ELISA testing

A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.

Rapid testing

Julie Bottero, MD

With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year, hepatitis B is currently a frequent and potentially severe disease in France, despite efforts towards prevention and effective care.

In terms of prevention, France has very low immunization coverage (27.7%) and a high percentage of people ignoring HBV status (55%), leading to a delay in care. This is partly explained by poor knowledge of hepatitis B infection in the general population and an underestimation of the health impact of hepatitis B by doctors and health officials. Until recently, there have been no national guidelines governing its implementation (which is variable depending on the structures where screening is performed) and an insufficient evaluation of screening practices. Thus, data on the severity of liver disease, indications for treatment of HBV-infected patients and data on the use of vaccination for nonimmunized people are scarce. Furthermore, while HIV rapid tests are beginning to be used more widely, particularly to address the issue of people who do not come back and collect their results and to better adapt "counselling", their usefulness to detect of hepatitis B virus has not been evaluated to date.

The main objective of the Optiscreen B Study is to determine the benefit, if any, of using rapid tests as a screening tool to improve diagnosis, care and prevention of hepatitis B. Individuals risk of HBV-infection will be randomized into 2 groups, one group for which screening will be performed by usual serological test and a second group for which screening will be based on rapid tests. Centers will be selected to represent a diverse range of health centers whose aims include screening, prevention and/or vaccination.

Application of HBV Rapid Tests as a Tool for Wide-Use Screening

Is the Combination of Screening Algorithms and Use of Hepatitis B Rapid Tests Useful in Optimizing the Screening and Prevention of Hepatitis B?

Data will be shared upon official request by interested parties. All requests are subject to approval by the Scientific Committee.

Subjects who are considered required to seek further care are as follows:

* those who need HBV vaccination (non-immunized)
* those who are infected with hepatitis B virus (infected)

Of these patients, subjects who have achieved appropriate care are considered as follows:

* non immunized subjects who have initiated HBV vaccination sequence (vaccinated)
* infected subjects who seek health care at a specialized center, allowing to quantify the severity of liver-related disease (infected with care)

The percentage of patients appropriately seeking care will be then calculated by the following formula:

((nb Vaccinated + nb infected with care) / (nb non-immunized + nb infected))\*100

ANRS, Emerging Infectious Diseases

Gilead Sciences

Roche Pharma AG

Mairie de Paris

BioMérieux

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Any event possibly related to physical HBV test.

HBV infection status determined by enzyme-linked immuno-assay (ELISA)

ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).

ELISA Testing

HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).

ELISA testing: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).

Rapid testing: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.

Rapid Testing

Total

Age, Continuous

Sex: Female, Male

Low (<2.0%)

Intermediate (2.0-8.0%)

High (>8.0%)

HBV prevalence of birth country

Social security

Health insurance plan

All participants completing their intervention.

Low prevalence of HBV infection; individuals with barriers to healthcare were underrepresented; Quick Profile anti-HBsAb rapid test unable to confirm nonimmunized status; intervention had same-day blood draws, which is not done in routine practice.

Dr. Julie Bottero

Power calculations were performed to detect \>15% difference in immediate linkage-to-care and vaccination. We hypothesized from discussions with an expert panel that \~30% of participants would have appropriate care with standard HBV serology. Assuming type 1 error=0.05 and power=80%, 152 participants per arm would be needed. As \~40% of the population would be nonimmunized or HBsAg-positive from previous data, a minimum 375 participants per arm would be required.

Only participants needing further medical intervention were included in analysis: non-immunized (HBsAg negative, anti-HBc antibody negative, anti-HBs antibody negative) or infected (HBsAg positive).

Percentage of Patients Appropriately Seeking Care

Overall Study

Toxoplasmosis

Coccidioidomycosis

Coccidiosis

Protozoan Infections

Parasitic Diseases

Immunoglobulin M

50 cancer patients referred to the Oncology Department, Faculty of medicine, Sohag University.

50 healthy controls will be recruited in the study.

ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.

ELISA

Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.

DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.

Sequencing

Eman FF Mohammed, Ass lecturer

Mohammed EM Tolba, Prof Dr

Eman FF Mohammed, MSc

I. Evaluation of T. gondii infection in cancer patients using different serological markers.

II. Studying genetic lineages infecting cancer patients in Sohag Governorate to predict clinical course and therapeutic needs using B1 and RE genes.

The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Patients with cancer have deficient cellular immunity and are potentially susceptible to opportunistic infections including Toxoplasma gondii (T. gondii). Few reports are available about toxoplasmosis in this group of patients. In recent years, it has emerged as an important life-threatening opportunistic pathogen in immunocompromised patients.

T. gondii is a ubiquitous obligate intracellular protozoan parasite that can infect virtually any nucleated vertebrate cell. T. gondii is one of the most successful parasites worldwide, with upwards of 30% of the human population infected.

While T. gondii infection in immunocompetent individuals is usually asymptomatic, it is more detrimental in immunocompromised individuals, such as those with HIV, patients receiving organ transplants or undergoing cancer treatment. A variety of malignancies, including lymphoma, leukemia, and myeloma, can reactivate toxoplasmosis. Moreover, T. gondii is incriminated to be responsible for the progression of malignant diseases.

Screening of toxoplasmosis in cancer patients is mandatory to guard against life-threatening disseminated disease. Diagnosis rely mainly on serology. A study in 2018 was performed to assess the prevalence of anti-T. gondii antibody among cancer patients in Cairo-Egypt. Among 180 cancer patients, a total of 110 patients (61.1%) were positive for anti-T. gondii antibodies. Till now there is no screening program in Egypt for toxoplasmosis in cancer patients although recently demonstrated to be at high risk for acquiring the infection with life-threatening sequelae.

Despite the significant improvements in serological methods, there are still unresolvable limitations such as inability of these methods to confirm the presence of parasite in immunocompromised patients. To overcome these limitations, different molecular methods including conventional PCR (cn PCR), nested PCR, real-time PCR (qPCR) and also loop-mediated isothermal amplification (LAMP) techniques have been developed to detect T. gondii DNA in biological samples.

As molecular diagnosis is not depending on the immunological condition of the host, it would be ideal for cancer patients. The ability of molecular methods to detect low amounts of parasites in fluids or tissues is a key issue, as Toxoplasma can circulate at low concentrations, or inconstantly.

T. gondii has been considered a single species in the genus Toxoplasma. Early studies on the parasite strains from North America and Europe identified limited genetic diversity, which were classified into three clonal lineages I, II, and III.

Genotyping of isolates from all continents revealed a complex population structure. Recent research supports the notion that T. gondii genotype may be associated with disease severity. The outcome of toxoplasmosis is related primarily to host and parasite genetics.

The first PCR technique for T. gondii detection was established by Burg and colleagues in which the 35-repeat B1 gene of T. gondii genome was amplified. Following it, several multi-copy targeting genes including 18S rRNA-, P30-,529-bp repeat fragment or the AF146527 element have been used for the detection of T. gondii in different biological samples.

In spite of the growing data concerning T. gondii genotypes and its role in epidemiological and biological studies,very few studies have been reported in Egypt until now. It is essential to genetically define and characterize T. gondii strains isolated from cancer patients to understand the population genetic structure, population biology, and pathogenesis of this important pathogen in our locality using the highly sensitive molecular techniques.

To the best of our knowledge, this is the first study in Egypt to reveal the population structure of T. gondii in patients with cancer.

Blood samples in EDTA tubes for molecular detection of Toxoplasma gondii gene then for sequencing.

Genetic Diversity of Toxoplasma Gondii in Cancer Patients

Sohag University

Teaching assistant of medical parasitology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Renal Cell

Lung Neoplasms

Kidney Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Antineoplastic Agents

Nivolumab

Antibodies, Monoclonal

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.

Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.

Pharmacokinetic of Nivolumab

Claude Linassier

To assess the relationship between progression free survival of patients treated with nivolumab for metastatic non small cell lung carcinoma or a metastatic renal cell carcinoma and nivolumab blood concentration.

Collection of standard data prospectively.

Nivolumab is a monoclonal antibody used for the treatment of non small cell lung carcinoma and renal cell carcinoma. Huge variability exists between patients treated by nivolumab in terms of efficacy and side effects. Like others monoclonal antibodies, a relation between concentration and effects of nivolumab may exist.

The aim of this study is to assess the relationship between blood concentration of nivolumab and progression free survival, overall survival and side effects on the one hand, and on the other to describe pharmacokinetic of nivolumab

Blood samples will be drawn to all patients to measure nivolumab concentration

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

Association between nivolumab concentration and progression free survival : time from start of nivolumab treatment to progression

Association between nivolumab concentration and overall survival : time from start of nivolumab treatment to death

Determination of nivolumab concentration associated with clinical benefit (complete response + partial response + stable disease)

Association between nivolumab residual concentration and side effects

Nivolumab residual concentrations will be measured each 14 days until the end of the study (up to one year).

University Hospital, Tours

Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

Mouth and Tooth Diseases

Immune System Diseases

Diabetes Mellitus

Gingivitis

Diabetes Mellitus, Type 1

Necrosis

Periodontal Diseases

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Autoimmune Diseases

Mouth Diseases

Stomatognathic Diseases

Gingival Diseases

Children with type 1 diabetes mellitus and gingivitis

Children with type 1 diabetes mellitus and healthy gingiva

Systemically healthy patients with gingivitis

Systemically healthy patients with healthy gingiva

Sultan KELES, Dr.

This study aimed to evaluate the levels of interleukin 18 and tumor necrosis factor-alpha (TNF-α) in gingival crevicular fluid (GCF) of children with type 1 diabetes mellitus and gingivitis.

Eighty eight children (44 with type 1 diabetes mellitus and 44 healty; age range 7-14 years) will be recruited for the study. The children will be classified into four subgroups based on their periodontal status; 1) Children with gingivitis and diabetes mellitus (MG, n=22); 2) Children with type 1 diabetes mellitus with healthy periodontium (MH, n=22); 3)Healthy children with gingivitis (HG, n=22); 4) Healthy children with healthy periodontium (HH, n=22). Probing pocket depth (PPD), gingival index (GI) and plaque index (PI) will be recorded. Interleukin-18 and TNF-α will be analyzed in GCF and saliva samples by ELISA.

Tumor Necrosis Factor-alpha and Interleukin-18 Levels in Children With Gingivitis and Type 1 Diabetes Mellitus

Gingival Crevicular Fluid Tumor Necrosis Factor-alpha and Interleukin-18 Levels in Children With Gingivitis and Type 1 Diabetes Mellitus

Aydin Adnan Menderes University

Assist. Prof.Dr.

Carcinoma, Squamous Cell

Mouth Neoplasms

Squamous Cell Carcinoma of Head and Neck

Neoplasms, Squamous Cell

Head and Neck Neoplasms

Oral Squamous Cell Carcinoma

Oral Cancer

Lip and Oral Cavity Cancer

Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.

Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.

Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.

Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.

Saliva sampling

Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.

High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.

HPLC

Darko Macan, PhD, DDS

According to the World Health Organization, oral cancer (OC) is the eighth most common cancer in the world with a five year survival rate of 50%.

Oral cancer tumor cells produce biochemical substances, tumor markers, differed from healthy individuals in expression or quantitative ratio, detectable in tissues and/or body fluids.

Saliva, because of its accessibility, proximity and noninvasive approach, presents an ideal tool for the research of oral cancer tumor markers.

The aim of this study will be to isolate, quantify, analyze the role and describe the kinetics of diadenosine tetraphosphate (Ap4A), Squamous Cell Carcinoma associated Antigen (SCCA), Trophoblast cell surface antigen (TROP2) in patients with OC, potentially malignant disorders (PMOD) and age and sex matched control group with a clear medical history.

There are number of studies published on OC tumor markers isolated mostly in serum, however the satisfactory specificity and sensitivity still hasn't been reached.

Liquid chromatography-ion trap-mass spectrometry, Multiple Reaction Monitoring method (LC-IT-MS, MRM) will be developed to isolate and quantify the above mentioned tumor markers. This method has not yet been used to quantify the above mentioned salivary tumor markers. Ap4A and TROP2 have never been isolated from saliva.

The aim is to develop a tumor-specific test with a satisfactory statistical sensitivity and specificity and dynamically measure the levels of tumor markers, before and immediately after therapy - surgery/radiotherapy/chemotherapy or their combination, and during regular follow-up one and two years after surgery. As another novelty, the investigators aim to determine the markers circadian rhythm.

A OC tumor specific test, with satisfactory sensitivity and specificity, would enable earlier OC diagnosis, possibly before the clinical appearance, raise the survival rate of OC patients, enable early diagnosis of recurrence and/or new primary tumors and ensure better post-treatment life-quality.

In the last few years, treatment of oral cancer (OC) showed improvement due to the combined efforts of surgery, radiotherapy and chemotherapy. Nevertheless the long-term survival rate, only marginally improved with a five year survival rate of 50%.

OC is preceded by a preinvasive stage, which may last for many years. Tumor progression in epithelia has been classified as normal, hyperplastic (non-dysplastic), dysplastic carcinoma in situ and invasive carcinoma. The majority of the initial alterations of precancerous and cancerous oral lesions are often non recognizable, even by histopathological examination. The basic biology of initiation and progression of these tumors is still obscure. Carcinogenesis is a process which includes initiation, promotion and progression, driven by accumulation of specific altered genes. Tumor cells produce biochemical substances called tumor markers. Some of these substances found in healthy individuals, but with altered quantitative ratio. Besides the salivary DNA and RNA, other markers are detectable in saliva, such as cell cycle markers (p53, p16 etc.), growth factors (EGF, TGF, etc.), cell surface markers, oxidants and antioxidants and other. Because of its accessibility, non-invasive approach and location proximity, saliva presents an ideal tool for the research of OC tumor markers.

This study will analyze the role of Diadenosine tetraphosphate (Ap4A), Squamous Cell Carcinoma associated Antigen 1 and 2 (SCCA1 and 2) and Trophoblast Cell Surface Antigen (TROP2) in the development of OC.

Ap4A is the only diadenosine polyphosphate that can induce a considerable increase in \[Ca2+\] in endothelial cells, indicating that its vasoactive effects are comparable to the known effects of arginine vasopressin, angiotensin II and adenosine triphosphate (ATP). Ap4A is a ubiquitous diadenosine polyphosphate signal molecule for DNA replication in mammalian cell.

Level of Ap4A was found to be directly related to the proliferative activity of the cells. It is considered that the Ap4A has an important role in the regulation of cellular growth and division. In the absence of the tumor suppressor gene FHIT (Fragile Histidine Triad), located on the chromosome 3p, Ap4a accumulates and leads to DNA synthesis and multiplication of cells. Loss of heterozygosity of the chromosome 3p is believed to be a common event in the early phase of carcinogenesis.

Ap4A could represent a tumor marker for the early stages of carcinogenesis. Possibly it could indicate carcinogenesis earlier than pathohistological diagnostics. Ap4a has never been isolated in saliva or measured in OC and PMOD patients.

In healthy individuals, SCCA, a glycoprotein, is located inside the cell. In individuals with OC it is released from the cell and thereby, is detectable in serum and saliva. Recent reports have shown that SCCA can influence the invasion or metastasis of cancer cells. However, it remains unclear how SCCA acts to mediate these biological functions. SCCA has already been presented as a potential serum marker for pathologic lymph node metastasis, advanced tumor stage, and an increased rate of distant metastasis in patients with OC, however, never has it been isolated in saliva in OC patients. It has never been measured in patients with PMOD.

The human trophoblast cell-surface antigen, TROP2 (also termed GA733-1, M1S1, EGP-1) is encoded by the TACSTD2 gene, which is mapped to the human chromosome 1p32. TROP2 function and role is still not well understood, although it has previously been suggested that it played a role in growth regulation of cancer cells, as well as in fetal lung formation as a calcium signal transducer. Two studies showed that TROP2 over-expression may emerge as a prognostic tool in patients with oral and laryngeal squamous cell carcinoma. TROP2 antigen has never been isolated or measured in saliva in OC and PMOD patients. OC tumor-specific test will probably have to involve two or all of the above described tumor markers. However, salivary Ap4a alone could present a marker for the earliest stages of OC carcinogenesis. Therefore, it could reveal carcinogenesis before the clinical appearance of OC. The investigators believe that saliva proximity to OC could enable even higher specificity. As another novelty, determining the circadian rhythm of the above mentioned markers should provide more information on their kinetics and role in OC carcinogenesis and rule out any potential confounders, such as the influence of a certain nutritive or the influence of some habits e.g. smoking.

Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients

Isolation, Quantification and Kinetics of Salivary Ap4A, SCCA and TROP2 in Patients With Oral Cancer and Potentially Malignant Oral Disorders

Salivary tumor marker levels before surgery

Salivary tumor marker levels after surgery

Croatian Science Foundation

University of Zagreb

Professor, PhD

This study aimed to evaluate the levels of interleukin 10, interleukin 6, interleukin 32 and tumor necrosis factor-alpha (TNF-α) in saliva of children with early childhood caries.

Fifty six children ( 28 with early childhood caries and 28 without early childhood caries ; age range 3-6 years) will be recruited for the study. Probing pocket depth (PPD), gingival index (GI) and plaque index (PI) will be recorded and saliva samples will be collected. Interleukin-32, Interleukin-10, Interleukin-6 and TNF-α will be analyzed in saliva samples by ELISA.

Salivary Interleukin-32, Interleukin-10, Interleukin-6 and Tumor Necrosis Factor-alpha Levels in Children

Evaluation of Salivary Interleukin-32, Interleukin-10, Interleukin-6 and Tumor Necrosis Factor-alpha Levels in Children With Early Childhood Caries.

Assoc.Prof.Dr.

23 age-and-sex-matched healthy individuals, as normal controls

quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.

Fayoum University

The study will include patients with oral cancer and healthy controls of both sexes. Subjects having any systemic diseases or other types of cancer will be excluded. All subjects will be selected from Oral Medicine Department, Faculty of Dentistry, Al Ahram Canadian University and Fayoum University. Informed consent will be obtained from all subjects enrolled in this study after explanation of the whole procedure.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Application of HBV Rapid Tests as a Tool for Wide-Use Screening	NCT01767597	Hepatitis B Liver Cirrhosis Carcinoma, Hepa...	ELISA testing Rapid testing	18 Years -	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Genetic Diversity of Toxoplasma Gondii in Cancer Patients	NCT04834076	Toxoplasma Gond... Cancer	ELISA PCR Sequencing	1 Year -	Sohag University
Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer	NCT03433534	Kidney Cancer Lung Cancer	Pharmacokinetic...	18 Years -	University Hospital, Tours
Tumor Necrosis Factor-alpha and Interleukin-18 Levels in Children With Gingivitis and Type 1 Diabetes Mellitus	NCT03910205	Periodontal Dis...	ELISA	7 Years - 14 Years	Aydin Adnan Menderes University
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients	NCT03529604	Oral Cavity Squ... Saliva Altered Precancerous Le...	Saliva sampling ELISA HPLC	-	University of Zagreb
Salivary Interleukin-32, Interleukin-10, Interleukin-6 and Tumor Necrosis Factor-alpha Levels in Children	NCT04958005	Early Childhood...	ELISA	3 Years - 70 Months	Aydin Adnan Menderes University
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study	NCT06031337	Oral Cancer Oral Squamous C...	ELISA	12 Years -	Fayoum University
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients	NCT03529604	Oral Cavity Squ... Saliva Altered Precancerous Le...	Saliva sampling ELISA HPLC	-	University of Zagreb
Application of HBV Rapid Tests as a Tool for Wide-Use Screening	NCT01767597	Hepatitis B Liver Cirrhosis Carcinoma, Hepa...	ELISA testing Rapid testing	18 Years -	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Spots Global Cancer Trial Database for elisa

Every month we try and update this database with for elisa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for elisa

Every month we try and update this database with for elisa cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for elisa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.